In this video Dr Shahzad Raza discusses updated efficacy and safety data from the phase II RedirecTT-1 study evaluating the combination of talquetamab (anti-GPRC5D×CD3) and teclistamab (anti-BCMA×CD3) in patients with triple-class exposed relapsed/refractory multiple myeloma and true extramedullary disease (EMD).

He highlights high overall and complete response rates observed with the dual bispecific antibody approach, durable progression-free survival, and outcomes across different EMD locations. Particular attention is given to a novel analysis of total EMD tumour volume as a potential prognostic factor for response.

He also reviews the safety profile of the combination, including cytokine release syndrome, infections, and neurotoxicity, and places these findings in the context of existing therapies for this high-risk population with significant unmet clinical need.